Explore our ACCC 2020 Impact Report, the Oncology Issues, Vol.36 N.5, and our video podcast, CANCER BUZZ TV.
 

Share

    


Home / Learn / Cancer Types / Ovarian Cancer / SGO/ACCC Joint Education Collaborative

SGO/ACCC Joint Education Collaborative

Optimizing Outcomes in Ovarian Cancer Using Personalized Medicine

The Society of Gynecologic Oncology (SGO) and the Association of Community Cancer Centers (ACCC) have been awarded a joint independent medical education grant from AstraZeneca and Merck. Together, SGO and ACCC will offer four accredited webinars (live and enduring) and up to six additional non-accredited media presentations on the topic of delivering personalized medicine in a community setting.

Podcast

Conversations in the Clinic: Patient Perspectives on Genetic Testing

Listeners will learn about the importance of genetic testing for ovarian cancer from a genetic counselor and a physician, and most importantly, from a patient.

Moderator: Ashley Stuckey, MD
Speakers: Todd Tillmanns, MD, FACOG, West Cancer Center, and Leigha Senter-Jamieson, MS, CGC, The Ohio State University Wexner Medical Center.

Steering Committee

William Burke, MD, Stony Brook University Cancer Center
Melissa Hardesty, MD, MPH, Alaska Women’s Cancer Care
Premal Thaker, MD, MS, Washington University in St. Louis, Siteman Cancer Center
Ashley Stuckey, MD, Brown University, Women and Infants Hospital
Todd Tillmanns, MD, FACOG, West Cancer Center

Jeff Lin, MD, City of Hope Medical Group
Roisin O’Cearbhaill, MD, Memorial Sloan Kettering Cancer Center
Charles Drescher, MD, Swedish Cancer Institute
John Farley, MD, COL, FACOG, FACS, Dignity Health Cancer Institute, St. Joseph’s Hospital and Medical Center
Leigha Senter-Jamieson, MS, CGC, The Ohio State University Wexner Medical Center

 

Target Audience

Medical oncologists, gynecologic oncologists, obstetrician-gynecologists, primary care physicians, advanced practice providers (nurse practitioners, physician assistants, oncology pharmacists), oncology nurses, pathologists, and other healthcare professionals (HCPs) involved in treating patients with ovarian cancer.

Learning Objectives

At the end of this educational initiative, participants should be able to:

  • Discuss the utility of novel biomarkers such as homologous repair deficiency (HRD) genomic instability for personalizing therapy in patients with ovarian cancer
  • Assess the clinical rationale for tumor and HRD genomic instability testing, including differentiation of germline/familial risk assessment versus tumor profiling in patients with ovarian cancer
  • Implement monitoring strategies and manage adverse events of emerging targeted therapies for patients with ovarian cancer
  • Explore strategies to improve patient engagement in shared decision-making regarding biomarker testing and personalized treatment in ovarian cancer along the continuum of care

Accreditations

The live/online webinars will each offer the following credits:

  • CME: 0.5 AMA PRA Category 1 Credit(s)™
  • ACPE credit: 0.5 contact hour
  • ANCC credit: 0.5 contact hour

Non-accredited educational materials: podcasts, case reviews, and other educational resources/tools.

Evaluation and Outcomes

The impact of participating in this initiative on clinical performance related to the optimal management of ovarian cancer will be assessed by comparing the response for pre-activity and post-activity tests (also designed by the Steering Committee). The outcomes analysis will assess the effectiveness of the programs in changing knowledge and competence, and intent to change behavior among learners in the following areas:

  • Learners will have a better understanding of utility of novel biomarkers such as homologous repair deficiency (HRD) genomic instability for personalizing therapy in patients with ovarian cancer
  • Learners will correctly assess the clinical rationale for tumor and HRD genomic instability testing, including differentiation of germline/familial risk assessment versus tumor profiling for therapeutic implications in ovarian cancer patients
  • Learners will be better prepared to monitor and manage adverse events for emerging targeted therapies for patients with and ovarian cancer
  • Learners will be more familiar with implementing strategies to improve engage patients in shared decision-making regarding biomarker testing and personalized treatment in ovarian cancer throughout the continuum of care starting at diagnosis

If you have any questions or feedback about this project, please contact Sandra Megally, Senior Program Manager.

Our Partner

SGO-200x114

Our Supporters

astrazeneca-200x80
merck-200x80

This activity is supported by independent medical education grants from AstraZeneca and Merck.